Erectile Dysfunction Drugs as Potential Therapy for Cognitive Decline: Preclinical and Translational Evidence

Erectile dysfunction (ED) and cognitive decline share overlapping vascular, metabolic, and neurodegenerative mechanisms, particularly in aging populations. Phosphodiesterase type 5 inhibitors (PDE5-Is), such as sildenafil and vardenafil, are widely used to treat ED by elevating cyclic guanosine mono...

Full description

Bibliographic Details
Published in:	Cells
Main Author:	Roberta Ricciarelli
Format:	Article
Language:	English
Published:	MDPI AG 2025-09-01
Subjects:	phosphodiesterases vardenafil sildenafil NO/cGMP Alzheimer’s disease
Online Access:	https://www.mdpi.com/2073-4409/14/19/1505

Similar Items

Optogenetic manipulation of cyclic guanosine monophosphate to probe phosphodiesterase activities in megakaryocytes
by: Yujing Zhang, et al.
Published: (2022-08-01)

Memory Enhancers for Alzheimer’s Dementia: Focus on cGMP
by: Ernesto Fedele, et al.
Published: (2021-01-01)

Phosphodiesterase 5 (PDE-5) inhibitors (sildenafil, tadalafil, and vardenafil) effects on esophageal motility: a systematic review
by: Arman Shafiee, et al.
Published: (2023-05-01)

Effect of topically applied sildenafil citrate on wound healing: experimental study
by: Koray Gürsoy, et al.
Published: (2014-08-01)

Assessment of exercise tolerance using cardiopulmonary exercise test in patients with chronic obstructive pulmonary disease and secondary pulmonary arterial hypertension treated with Sildenafil versus those receiving only standard-of-care
by: Darwish Ibrahim Darwish, et al.
Published: (2024-07-01)

Regulation of the renin-angiotensin-aldosterone system by cyclic nucleotides and phosphodiesterases
by: Stepan Gambaryan, et al.
Published: (2023-08-01)

Compartmentation of cGMP Signaling in Induced Pluripotent Stem Cell Derived Cardiomyocytes during Prolonged Culture
by: Maria Faleeva, et al.
Published: (2022-10-01)

The Emerging Role of Phosphodiesterase 5 Inhibition in Neurological Disorders: The State of the Art
by: Clara Crescioli, et al.
Published: (2024-10-01)

Evolution of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction in Taiwan
by: Bang-Ping Jiann
Published: (2016-06-01)

Influence of regular use of vardenafil on endothelial and erectile functions in patients with arteriogenic erectile dysfunction
by: Safar Israilovich Gamidov, et al.
Published: (2009-10-01)

The Sleep Quality- and Myopia-Linked PDE11A-Y727C Variant Impacts Neural Physiology by Reducing Catalytic Activity and Altering Subcellular Compartmentalization of the Enzyme
by: Irina Sbornova, et al.
Published: (2023-12-01)

New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil
by: Marian Cruz-Burgos, et al.
Published: (2021-02-01)

Characterization and Modification of Light-Sensitive Phosphodiesterases from Choanoflagellates
by: Yuehui Tian, et al.
Published: (2022-01-01)

Phosphodiesterase Type 5 Inhibitors Greatly Affect Physicochemical Properties of Model Lipid Membranes
by: Anastasiia A. Zakharova, et al.
Published: (2021-11-01)

Apicomplexan phosphodiesterases in cyclic nucleotide turnover: conservation, function, and therapeutic potential
by: William J. Moss, et al.
Published: (2024-02-01)

Dysregulated Cyclic Nucleotide Metabolism in Alcohol-Associated Steatohepatitis: Implications for Novel Targeted Therapies
by: Diego Montoya-Durango, et al.
Published: (2023-10-01)

Counterfeiting honey with phosphodiesterase inhibitors for sexual activity enhancement: detection using high-performance liquid chromatography coupled with a photodiode array detector (HPLC-PAD)
by: Abdullah M. Alkhalaf, et al.
Published: (2024-04-01)

Regulation and Pharmacology of the Cyclic GMP and Nitric Oxide Pathway in Embryonic and Adult Stem Cells
by: Alexander Y. Kots, et al.
Published: (2024-12-01)

Schlafen4+-MDSC in Helicobacter-induced gastric metaplasia reveals role for GTPases
by: Lin Ding, et al.
Published: (2023-06-01)

Phosphodiesterase and psychiatric disorders: a two-sample Mendelian randomization study
by: Miaomiao Jiang, et al.
Published: (2023-08-01)

The choice of the medicine phosphodiesterase inhibitors of 5th type for treating patients with erectile dysfunction and chronic prostatitis
by: P. V. Glybochko, et al.
Published: (2013-06-01)

REVITALISE: A Large Observational Study Assessing the Safety and Effectiveness of Vardenafil in Men With Erectile Dysfunction and Metabolic Syndrome
by: Ridwan Shabsigh, MD, FACS, et al.
Published: (2016-09-01)

Pde5a deficiency prevents diet-induced obesity via adipose cAMP-PKA activation enhancing fat browning
by: Federica Campolo, et al.
Published: (2025-11-01)

Phosphodiesterases regulate BAY 41-2272-induced VASP phosphorylation in vascular smooth muscle cells
by: Shaquria P Adderley, et al.
Published: (2012-02-01)

Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives
by: Ahmed K. ElHady, et al.
Published: (2023-09-01)

Analysis of <it>PDE6D </it>and <it>PDE6G </it>genes for generalised progressive retinal atrophy (gPRA) mutations in dogs
by: Dekomien Gabriele, et al.
Published: (2003-07-01)

Spectrofluorimetric determination of cyclic guanosine monophosphate in human nasal secretions: evaluating levels in healthy individuals and patients with olfactory dysfunction
by: Mohamed H. Abdelazim, et al.
Published: (2025-06-01)

Sildenafil Citrate Oral Suspension for Managing Erectile Dysfunction: A Systematic Review and a Consensus Report from the Italian Society of Andrology (SIA)
by: Carlos Miacola, et al.
Published: (2024-08-01)

A mini-review: phosphodiesterases in charge to balance intracellular cAMP during T-cell activation
by: Marie Bielenberg, et al.
Published: (2024-03-01)

Investigation of Cnidium monnieri compounds as phosphodiesterase-5 antagonists in erectile dysfunction via molecular docking and dynamic simulation
by: Damilola Alex Omoboyowa
Published: (2024-01-01)

Role of Phosphodiesterase 1 in the Regulation of Real-Time cGMP Levels and Contractility in Adult Mouse Cardiomyocytes
by: Nadja I. Bork, et al.
Published: (2023-12-01)

ROCK and PDE-5 Inhibitors for the Treatment of Dementia: Literature Review and Meta-Analysis
by: Dong-Hun Lee, et al.
Published: (2022-06-01)

The efficacy and molecular mechanism of the effect of schisandrin b on the treatment of erectile dysfunction
by: WEI LIU, et al.
Published: (2019-08-01)

A novel phosphodiesterase target as a therapeutic approach: inhibiting DEN-induced hepatocellular carcinoma progression
by: Anil Kumar, et al.
Published: (2025-03-01)

The Effect of Chronic Treatment with the Inhibitor of Phosphodiesterase 5 (PDE5), Sildenafil, in Combination with L-DOPA on Asymmetric Behavior and Monoamine Catabolism in the Striatum and Substantia Nigra of Unilaterally 6-OHDA-Lesioned Rats
by: Elżbieta Lorenc-Koci, et al.
Published: (2024-09-01)

Roles of Cyclic Nucleotide Phosphodiesterases in Signal Transduction Pathways in the Nematode <i>Caenorhabditis elegans</i>
by: Kranti K. Galande, et al.
Published: (2025-07-01)

Hyperammonemia impairs long-term potentiation in hippocampus by altering the modulation of cGMP-degrading phosphodiesterase by protein kinase G
by: Pilar Monfort, et al.
Published: (2004-02-01)

A Perspective on Natural and Nature-Inspired Small Molecules Targeting Phosphodiesterase 9 (PDE9): Chances and Challenges against Neurodegeneration
by: Giovanni Ribaudo, et al.
Published: (2021-01-01)

Membrane-Mediated Action of Phosphodiesterase 5 Inhibitors
by: Anna I. Malykhina, et al.
Published: (2025-04-01)

Haploinsufficiency of PDE2A causes in mice increased exploratory behavior associated with upregulation of neural nitric oxide synthase in the striatum
by: Ana Gabriela de Oliveira do Rêgo, et al.
Published: (2025-02-01)